Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Post Traumatic Stress DisorderOpioid-use Disorder
Interventions
DRUG

Lofexidine

BID dosing, and a max daily dose of 1.6 mg/day

DRUG

Placebo oral tablet

Placebo

Trial Locations (2)

77030

RECRUITING

Michael E. DeBakey Veterans Affairs Medical Center, Houston

78229

RECRUITING

South Texas Veterans Health Care System, San Antonio

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

RTI International

OTHER

collaborator

Michael E. DeBakey VA Medical Center

FED

collaborator

USWM, LLC (dba US WorldMeds)

INDUSTRY

collaborator

Foundation for Advancing Veterans' Health Research

OTHER

lead

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

OTHER